British Columbia Drug and Poison Information Centre (BC DPIC)

Vertex Pharmaceuticals Incorporated today announced the U.S. Food and Drug Administration approved KALYDECO® (ivacaftor) to include use in children with cystic fibrosis ages 12 to <24 months who have at least one mutation in their cystic fibrosis transmembrane conductance regulator gene that is responsive to KALYDECO based on clinical and/or in vitro assay data.

Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).

The United States Food and Drug Administration (FDA) have announced the recall of two thyroid medications due to issues with their ingredients.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided "100% protection against a lethal dose of the Ebola virus" in a recent animal study published in The Journal of Infectious Diseases.

A powerful psychedelic compound found in ayahuasca can model near-death experiences in the brain, a study has found.

A Johns Hopkins expert panel of health care providers and patients have announced what is, to their knowledge, the nation's first set of operation-specific opioid prescribing guidelines.

Thirty jobs are to be created through a new £1.5m ‘Tele-Pharmacy’opening in Liverpool, aimed at helping people living with chronic care conditions to manage their medicinal needs through the UK’s only artificial intelligent mobile app ‘Now Patient’.